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Background
Clinical trials in the developing world sponsored by
industrialized countries raise numerous practical
and ethical difficulties. One critical challenge in
such trials is the comprehension of the informed
consent process by participants. While any clinical
trial will involve some degree of miscomprehension
with participants, where exactly, and to what
degree do these deficits exist [1,2]?
Problems in comprehension of informed consent
in rural and peri-urban Mali, West Africa
Michael T Krosina, Robert Klitzmanb, Bruce Levinb, Jianfeng Chengb and Megan L Ranneyb
Background Clinical trials undertaken by industrialized nations in undeveloped
nations pose several critical ethical dilemmas. One key potential problem con-
cerns misunderstandings of the consent process by participants. Though other
reports have begun to explore this area, needs remain to identify specific areas of
misunderstanding.
Purpose To identify deficits in comprehension during consent processes in Mali,
West Africa.
Methods After obtaining informed consent for participation for a malaria vaccine trial
being conducted in two West African villages, we administered to participants a 
nine-item questionnaire testing their understanding of information relevant for their
consent. After testing their ability to understand a multiple choice format, 78 of 100
subjects were administered the questionnaire in one village and 85 of 100 in the other.
Results Participants had difficulty comprehending several concepts relevant to
informed consent: 90% of respondents did not understand withdrawal criterion,
93% did not understand the existence of study side effects, and 74% did not
understand that they were enrolled in an investigation as opposed to receiving
therapy. The response rate and percentage of correct answers was generally much
higher in the village nearer an urban center than the more rural village. The percent
of correct answers exceeded 50% for five questions in the urban village and for only
two question in the more rural setting.
Limitations Potential limitations of this study are relating to translation, cultural
differences in the notion of informed consent, staff differences between each
village, the proportion who could not understand the survey instrument and the
fact that the study explored participants’ understanding of the consent process but
did not observe the process itself.
Conclusions This study illustrates potential areas of miscomprehension in the
consent process in a developing country. The degree of miscomprehension found in
this study appeared to be more than that found in similar studies conducted in
industrialized nations. Despite efforts to obtain truly informed consent, several factors
make it more challenging in the developing world. This research highlights the need
for more comprehensive studies of consent in developing countries. Such studies may
eventually aid investigators in identifying, targeting and addressing specific areas of
miscomprehension and thereby improve the informed consent process in the
developing world. Clinical Trials 2006; 3: 306–313. www.SCTjournal.com
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Prior studies
Several studies conducted in both Europe and the
United States have assessed the degree of under-
standing of the informed consent process, and have
illustrated flaws in comprehension [3]. Among con-
senting parents with children entering clinical trials
in nine European countries, the notion of volun-
tary withdrawal was particularly misunderstood,
with 20.7% of the parents miscomprehending the
concept [4]. In a clinical trial of a surgical proce-
dure, 33% of participants did not know they could
withdraw at any time [5]. In a study of experimen-
tal chemotherapeutic agents for cancer, 48% of
enrolled participants did not understand that the
investigation was of a “non-standard treatment,” [6]
and 38% did not understand the potential for risks
or side effects from the experimental chemother-
apy. A qualitative study in East Africa confirmed
many of these pitfalls in consent comprehension –
specifically, understanding of risk, research versus
treatment and autonomy. Interviews with consent-
ing individuals revealed common themes such as,
“It is inappropriate to question a doctor”, and
“there are no risks to this study . . . people at the
hospital have no bad intentions” [7]. While mis-
comprehension of consent is expected to some
degree, these studies show particular areas predis-
posed to misunderstanding. Yet questions remain
concerning the presence and degree of miscompre-
hension of studies in developing countries. With
increasing research conducted in developing
nations, and vast cultural barriers between partici-
pant and investigator, these questions are crucial.
Though little data exist on this topic, research in
the developing world, like that elsewhere, is predi-
cated ethically on proper informed consent.
We examined the consent process for a malaria
vaccine trial protocol in two villages in Mali, West
Africa. This trial was a preliminary survey studying
the incidence of both malaria and anemia for
cohorts randomized to either chloroquine or
placebo groups, along with minimal-risk weekly
medical screening of child subjects (aged six
months to five years). The trial’s endpoints were
malaria and anemia incidence with versus without
chloroquine regimens over the course of one
malaria season, to be later compared with use of
malaria vaccine. The consent process for the
malaria trial, which our team observed, was an oral
consent administered by a PI to groups of two to
four participants (ie, consenting parents) at a time.
It lasted for approximately 40 minutes. Periodic
breaks were taken to summarize and allow for ques-
tions as well as allotted time at the end for ques-
tions. Consent was given by thumbprint. All
aspects of the consent tested in our study were
explained at least twice to participants during this
group consent process. The process was interactive
to the extent that participants did regularly ask
questions during the process. The exact nature and
number of these questions was not quantified as
the observer (MK) does not speak native Bambara.
Methods
Questionnaire development and administration
This study was approved by the Malian IRB/Ethics
Committee as well as discussed with the IRB from
the sponsoring host country’s institution in July
2001. The questionnaire (Appendix) contains nine
questions that test details about the vaccine study’s
consent. Each question is intended to probe a spe-
cific area in the consent process and has one correct
answer, based on the vaccine study as explained
during the consent process. These areas are summa-
rized in Table 1. The questionnaire was developed
in concert with the Malian IRB, who deemed the
questions relevant and appropriate, over two ses-
sions. We focused on assessing understandings of
material presented in the consent process. It was
hoped that relevant areas of comprehension could
be examined. We based the questionnaire on obser-
vations of a few sessions of the informed consent
process, and intensive discussions with both promi-
nent village leaders and investigators. The question-
naire was translated from English to French by an
experienced translator, and back-translated from
French to English by a separate translator to ensure
translational accuracy. The test administrator who
orally delivered the test in each village was respon-
sible for translation from French to Bamabara (the
local language). The purpose and significance of the
project was discussed with the translators in order
to ensure as much as possible that they conducted
a culturally accurate translation. The test adminis-
trators were further trained on the importance of
objective and consistent delivery of the question-
naire, and observed by our team. The test was
multiple choice in nature. Due to illiteracy levels,
picture symbols (box, moon, smile, star) repre-
sented each choice. As this was in part a pilot study,
we did not seek separately to test the validity of
each question and the questionnaire as a whole.
In two different villages, 200 individuals con-
sented for participation in our study within 48
hours of the malaria trial’s initial consent process.
Groups of six to 14 participants were brought to
each village’s school, and seated at desks no less
than 4 feet away from one another to prevent
sharing of information. The test instructions were
then read. Two screening questions (with obvious
answers) were presented to ensure participants’
ability to understand and use the multiple-choice
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Table 1 Results of questionnaire
% Responses Village R % Responses Village U Total combined 
Question Topic N  78* N  85 % correct
1) Voluntary participation N  67 N  85 57%
a. Village elder 45% (30) 9% (8)
b. Yourself 21% (14) 85% (72)
c. Study team 21% (14) 5% (4)
d. Spouse 13% (9) 1% (1)
R  2 R  1
2) Compensation N  65 N  85 44%
a. Money and checkups 8% (5) 13% (11)
b. Malaria medicine and checkups 18% (12) 27% (23)
c. Food and checkups 28% (18) 56% (48)
d. Checkups only 46% (30) 4% (3)
R  2 R  1
3) Withdrawal criterion N  59 N  85 10%
a. At any time 12% (7) 9% (8)
b. With scientist’s permission 34% (20) 80% (68)
c. Village leader’s permission 20% (12) 6% (5)
d. Spouse’s permission 34% ( 20) 5% (4)
R  4 R  2 (low)
4) Withdrawal consequence N  37 N  85 44%
a. Checkups, but no food or money 27% (10) 45% (38)
b. Nothing and no healthcare access 11% (4) 6% (5)
c. Punished and fined 13% (5) 7% (6)
d. Nothing but healthcare access 49% (18) 42% (36)
R  1 R  2
5) Study versus treatment N  30 N  85 26%
a. Determine cause of malaria 53% ( 16) 26% (22)
b. Provide village with medicine 13% (4) 22% (19)
c. Study malaria/anemia incidence 20% (6) 28% (24)
d. Cure malaria in village 13% (4) 24% (20)
R  2 R  1
6) Study administration N  65 N  85 66%
a. Malian and U.S. scientists 43% (28) 84% (71)
b. Villagers 32% (21) 6% (5)
c. French government 12% (8) 8% (7)
d. Foreign company 12% (8) 2% (2)
e. Local political party 0% (0) 0% (0)
R  1 R  1
7) Randomization and placebo N  29 N  85 68%
a. Past medical history 24% (7) 12% (10)
b. Randomly 62% (18) 71% (60)
c. Social position 0% (0) 2% (2)
d. Current health 14% (4) 15% (13)
R  1 R  1
8) Side effects N  62 N  85 7%
a. Risks and side effects 10% (6) 6% (5)
b. Is a vaccine for life 27% (17) 25% (21)
c. No side effect 18% (11) 28% (24)
d. Will correct malnourishment 45% (28) 41% (35)
R  4 R  4
9) Lay scientific knowledge N 78 N  85 73%
a. Vegetation 14% (11) 6% (5)
b. Poor nutrition 9% (7) 5% (4)
c. Sadness 10% (8) 6% (5)
d. Night birds 4% (3) 1% (1)
e. Mosquitos 63% (49) 82% (70)
R  1 R  1
*Number eligible who answered screening questions adequately. See text.
N  number of interpretable responses for each question, R  Rank of correct answer (independent of percentage correct, when
ordered from most often chosen answer [1  1st] to least often [eg, 4  4th], when compared with other answer choices).
format. Any participant who chose an incorrect
answer for the first sample question had their
mistake explained to them, and was invited to try
the second practice question. Regardless of
performance on the first sample question, any par-
ticipant who did not answer the second sample
question correctly had his or her responses
excluded in entirety from the final results. Of the
remaining individuals included, any items not
answered, incomprehensibly marked or double
marked, were excluded individually from final
analysis. These exclusions explain the differences in
final sample size between the two villages, and in
number of respondents on each question. In village
R, on several questions, participants did not answer
or mistakenly double marked the questionnaire,
reflecting in part the lower level of education and
foreignness of testing in this village. The translator
administering the questionnaire was the only indi-
vidual who talked during the administration of the
questionnaire. To minimize sharing of information,
questions by participants were limited.
Study sites
To protect identity, the villages will be referred to as
“Village R” (for rural) and “Village U” (for urban).
Village R is a rural, agrarian village, 2.5 hours from
the Malian capital of Bamako. Its population is
approximately 8000; its economy is agrarian subsis-
tence farming, and it has no electricity. Greater
than 90% of consenting parents who took part in
the study had not attended school, and were
illiterate. Participants from Village R involved in the
questionnaire were 92% male, and had, on average,
2.5 children enrolled in the larger study. These
demographics for Village R suggest that the male
population works in close proximity to the village
(in farming) and is thus able to be present as head
of household, and that there are relatively larger
numbers of children per family as compared with
Village U.
Village U is a suburb of the capital city of
Bamako (25 minutes from the city center, directly
off Mali’s main highway). Its population is approx-
imately 13 000 and its economy is commerce-
oriented. It has electricity and telephones in over
60% of households. Since the majority of the men
work in the city, 83% of the consent for children to
participate in the vaccine study was given by the
female head of household. Of the consenting indi-
viduals (83% female, 13% male), 67% had primary
education and 70% were literate to some degree. In
general, the degree of education and political
awareness was greater in Village U than Village R.
Many of the villagers in Village U spoke French, but
Bambara was the primary language. Village U’s
consenting parents had, on average, 1.5 children
enrolled in the study, indicating smaller family size.
The expendable income per family, as demon-
strated by the presence of clothing and accessories,
was substantially higher than in Village R, and
access to “modern” goods and current news was
facilitated by the village’s urban proximity.
In each village, 100 consenting individuals
initially participated in our study and were ques-
tioned. In Village R, 100 out of 103 eligible parents
were questioned, with 78 participants eligible
following screening questions. In Village U, 100 out
of 167 eligible parents were questioned, with 85
participants eligible.
Statistical methods
We present results in this study both as absolute
percentages of participants who answered correctly,
as well as rank numbers comparing how the correct
answer choice faired against the other, incorrect
“decoy” answer choices. Statistical analyses were
performed using both a chi-squared and a binomial
test. The chi-squared statistic tested the null
hypothesis that respondents selected any answer
choice with equal probability without regard to the
correct answer (pure guess work), whereas the bino-
mial z-statistic tested the broader null hypothesis
that respondents selected the correct answer with
probability 0.20 (when there were five choices) or
0.25 (when there were four choices) irrespective of
their distribution across other incorrect choices. For
example, Question 1 in Village R gives a chi-squared
P-value of 0.005 and a binomial P-value of 0.22. The
chi-squared P-value of 0.005 allows one to reject
the null hypothesis that participants were guessing
at all answers, whereas the binomial P-value of 0.22
suggests that the proportion of people answering
correctly (21%) is not significantly different from
what we would expect by chance (25%). Because
the null hypotheses are nested (ie, pure guesswork
in all choices implies guesswork on the correct
choice), we used a “closed” test procedure, whereby
one tests the hypothesis of guesswork on the
correct choice if and only if one first rejects the
hypothesis of pure guesswork in all choices (by 
the chi-squared test at the 0.05 level). It is easy to
demonstrate that this closed test procedure controls
the probability of committing one or two type I
errors at the 0.05 level per item (see more generally
Marcus et al. [8] and Hochberg and Tamhane [9]). If
the chi-squared test was not significant at the 0.05
level, the procedure stopped – ie, we did not con-
sider the binomial test for this item. If the chi-
squared test was significant, we proceeded with the
binomial test at the 0.05 level, to address whether
or not the departure from pure guesswork favored
Consent comprehension assessment 309
www.SCTjournal.com Clinical Trials 2006; 3: 306–313
310 MT Krosin et al.
Clinical Trials 2006; 3: 306–313 www.SCTjournal.com
the correct answer. In addition, we also calculated
the 95% confidence interval for the percentage of
correct answers based on the method illustrated by
Daniel [10].
Results
The survey results are reported in Tables 1 and 2. As
previously noted, 22 of 100 participants in Village
U and 15 of 100 in Village R could not understand
the multiple choice format and were deemed ineli-
gible for this survey. Almost all eligible participants
answered every question in Village U, whereas
Village R had highly variable usable response rates,
between 37% (Q7) and 100% (Q9). This wide range
may have occurred due to lower level of education,
and consequent foreignness of testing. The chi-
squared test rejected the null hypothesis
(P  0.005) for all items in both villages separately,
indicating an overall pattern not consistent with
guessing, except for Questions 3 (P  0.05 in Village
R and 5 (P  0.87) in Village U. All of the binomial
results were significant, indicating a percentage for
the correct answer that statistically differed from
chance, except for questions about voluntary par-
ticipation (Q1), and compensation (Q2) in Village
R, and treatment versus research (Q5) in both vil-
lages, in which the percentage of correct responses
were 20–28% (close to chance). The percentage of
correct answers exceeded 50% for five questions in
Village U, and two questions in Village R. The
correct answer was the most frequent one chosen
for six questions in Village U and four questions in
Village R. The percentage of correct answers was sta-
tistically significantly higher in Village U than
Village R for four of the questions; voluntary partic-
ipation (85% versus 21%), compensation (56%
versus 28%), study administration (84% versus
43%) and knowledge about the cause of malaria
(82% versus 63%).
Discussion
While deficits with consent comprehension exist
universally, the results here illustrate the relative
degree of miscomprehension between demographi-
cally different towns in West Africa and, more impor-
tantly, miscomprehension in the developing world,
relative to industrialized nations. By focusing on
those areas with low percentages of correct responses,
problematic areas are best identified. As poor as these
results are, it is likely that the percentages of correct
answers observed here are high relative to the popu-
lation sampled, since 15% of questioned adults in
Village U and 22% in Village R could not reliably use
a multiple choice format, and were ineligible for
this survey. However, all of these individuals had
provided consent for the parent study.
The differences between Village R and Village U
can be attributed to several factors. In general, par-
ticipants from Village R answered incorrectly more
often than those from Village U. The most likely
reason for Village U’s better performance, as
described above, is Village U’s much higher percent-
age of literate adults and school attendance. While
demographics of age and sex invariably influences
response, the sample size impeded our ability to
control for these factors formally.
The most troublesome aspect of these results is
not just the extent of miscomprehension in certain
areas, but the relative degree of miscomprehension
when compared to studies conducted in industrial-
ized nations, particularly concerning withdrawal
criteria and side effects. As described above, studies
conducted in the United States and Europe have
illustrated that between 20% and 33% of partici-
pants miscomprehend withdrawal criterion [4,5],
while our study illustrates that 90% of participants
miscomprehended withdrawal criterion. Moreover,
the other three answer options for the question on
voluntary withdrawal – that the study team, the
village chief, or one’s spouse must give permission
Table 2 Statistical analysis of percentage of correct answers on questionnaire. The binomal P-value tests whether the reported
percentage deviates from the percentage expected by chance (ie, 25% for four-response questions and 20% for five-responses)
Village R Village U
Question P-value Percent correct (95% CI) P-value Percent correct (95% CI)
1) Voluntary participation 0.22 0.21 (0.11, 0.31) 0.005 0.85 (0.77, 0.93)
2) Compensation 0.31 0.28 (0.17, 0.39) 0.005 0.56 (0.46, 0.66)
3) Withdrawal criterion 0.01 0.12 (0.04, 0.20) 0.005 0.09 (0.03, 0.15)
4) Withdrawal consequence 0.005 0.49 (0.33, 0.65) 0.005 0.42 (0.32, 0.52)
5) Study versus treatment 0.26 0.20 (0.06, 0.34) 0.25 0.28 (0.18, 0.38)
6) Study administration 0.005 0.43 (0.31, 0.55) 0.005 0.84 (0.76, 0.92)
7) Randomization and placebo 0.005 0.62 (0.44, 0.80) 0.005 0.71 (0.61, 0.81)
8) Side effects 0.005 0.1 (0.02, 0.18) 0.005 0.06 (0.01, 0.11)
9) Lay scientific knowledge 0.005 0.63 (0.53, 0.73) 0.005 0.82 (0.74, 0.90)
for a child to withdraw – imply a perceived loss of
self-determination to withdraw from the study. A
consenting parent’s belief that third party permis-
sion is required to withdraw their child from the
study inherently implies the child may be kept in
the study despite the wishes of the parents or child.
The miscomprehension of drug side effects is
also troubling. While studies conducted in industri-
alized nations demonstrated 38% of participants
miscomprehending the existence of side effects [6],
in Village U and Village R, 93% of residents failed to
identify the existence of side effects with study
drugs. Misunderstood study risks have critical
ethical consequence. Other investigators have
noted that participants consistently identify the
existence of risks as the major impediment to par-
ticipating in research trials [11]. Without fully
understanding a study’s side effects, a participant
cannot make an informed decision as to the degree
of risk he/she is willing to accept by participating.
This trend of miscomprehension of side effects in
developing nations has been noted by others [6,12],
but the present data help provide a quantitative
assessment of this important phenomenon.
A final area of common miscomprehension
involved differentiation between study and treat-
ment. Question 5, evokes the so-called “therapeutic
misconception” [13,14], in which participants
mistake experimental research for effective treat-
ment. In Village R, 80% failed to understand that
researchers were providing an investigational agent,
as opposed to therapy. Though this miscomprehen-
sion may also exist in Village U, the statistical distri-
bution of responses was consistent with participants
guessing randomly, which is not reassuring, either.
As described above, a lower level of education and
literacy may correspond with a greater difficulty
understanding key aspects of research. A second
possibility may also be involved in Village R’s low
understanding of voluntary participation (Question
1). In a communal society, many believe that the
village chief or government directs actions.
Participants might presume a leader’s benevolence –
that the village chief or government would only
have citizens participate if the trial was therapeutic.
Other studies on trials in the developing world have
suggested, too, that the idea of informed consent
may be inappropriate in communal societies such as
those in Mali because consent can never be truly
“voluntary” in a society that values community
above individuality [15]. Whatever the reason is for
this misconception, and the degree to which it
exists in Village U as well, the ethical dilemma of
patients mistakenly expecting benefit from a no-
benefit study is apparent and should be taken seri-
ously in both rural and urban settings.
This study has several potential limitations. We
observed the consent process in both villages,
however did not formally assess its inherent quality
directly, but rather indirectly through participants’
understanding of it. Although the process was con-
sistently delivered by the same researchers in both
villages, both cultural and language barriers make
an accurate full assessment of the process itself dif-
ficult. In addition, different translators were used in
each of the two villages, making a complete statisti-
cal comparison between the two villages difficult.
However, the two translators received the same
instructions and training concerning this study and
the procedures involved. Moreover, despite differ-
ences in translation, the uniformity of ranking of
responses for each question between villages sug-
gests certain trends in miscomprehension and a
generally consistent translation effort.
The potentially threatening nature of “exams” in
schools, particularly for those who are illiterate and
had very little experience of schools may also have
affected results. The data here cannot be assumed to
be wholly generalizable to other developing nations
outside West Africa. However, this study suggested
a high degree of miscomprehension relative to
industrialized nations that highlights the need to
investigate further these areas in other countries
and contexts as well. As other cultures have differ-
ing understandings of autonomy and individuality,
Western standards in the consent process may be
somewhat inapplicable to other countries, because
of cultural reasons.
The present data do not address whether and to
what degree Western concepts of informed consent
are valid in the developing world. On the one hand,
critics argue that, “informed consent is neither nec-
essary nor sufficient for ethical clinical research”
[16], and that one need only the “capacity to under-
stand,” not a true understanding, for informed
consent to be valid [17]. Still others write that, “the
premise of informed consent as a rational decision
making process . . . may be perceived as an ideal in
the nature of a myth” [18]. Nonetheless, current
Western bioethical standards maintain at least the
ideal of informed consent as a critical aspect of
ethical clinical research. Thus, a strong argument
can be made that investigators working in develop-
ing nations have an ethical responsibility to insure
that their research subjects are as well-informed as
possible. These results also underscore the need to
consider innovative and creative approaches to
achieve that. Despite cultural differences regarding
informed consent, it appears to be appropriate to err
on the side of over-informing study participants, so
as to minimize the likelihood of participation deci-
sions being made based on faulty information.
Adverse events stemming from miscomprehension
occurring in a trial jeopardize not only that trial, but
also the larger relationship between foreign research
teams, foreign science, and developing nations.
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This study suggests several areas for future
research. First, qualitative methods can help
clarify several of the issues raised here as to how
participants understand the informed consent
process. For example, participants may feel that
they cannot withdraw at any time because either
they did not understand that this option was pre-
sented to them by the investigator, or they did not
believe (due to cultural attitudes and norms) that
such autonomy is in fact possible within the
context of their culture. Linguistically, future
research can assess why therapeutic misconception
remains such a difficult problem, and whether ways
may exist to address this misconception, within
these villages own language, that may better clarify
the differences between treatment and research.
This study illustrates degrees of miscomprehen-
sion in developing nations (that can be viewed in
comparison with other studies conducted in the
industrialized world), specific areas of miscompre-
hension in these countries, and needs for future
research. These data suggest certain areas of deficits
and can help investigators in tailoring their
informed consents to address these areas of mis-
comprehension. These data can also aid in increas-
ing understandings of what approaches toward
informed consent might be most ethically and
logistically appropriate. Moreover, studies such as
this one can benefit IRBs reviewing similar projects
to ensure as much comprehension of informed
consent as possible, as reflected in changes in
consent forms and procedures as well as periodic
assessments of the quality of the consent process.
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Appendix 1: Questionnaire
1) The participation of your child in the study—
a) — Was decided upon by the village leaders
as necessary.
b) — Was decided upon by you and your
husband and is completely optional. If
you do not want your child enrolled,
your child need not participate.
c) — Was decided upon by the scientists and
doctors.
d) — Was decided upon by your husband.
2) As compensation for participating in the
study, your family and your child will receive—
a) — A small amount of money in addition to
weekly physical checkups for your 
child.
b) — Malaria medicine everyday, money, and
weekly checkups for your child.
c)— A small amount of food (rice, millet or
sugar) in addition to weekly checkups
for your child.
d) — Weekly checkups, but nothing more.
6) This project is run by—
a) — Scientists and doctors working for the
governments of Mali and the United
States of America.
b) — Your village health and medical officials.
c) — The French government.
d) — A foreign company.
e) — Adama (local political party).
7) Children are selected to take this medicine—
a) — Based on a past medical history.
b) — By random assignment – like drawing
lots.
c) — Based on social position of family.
d) — Based on current health of child.
8) The medicine that some children receive—
a) — Will prevent malaria right now, but
carries a small risk of some side effects
such as rash, nausea, or other problems.
b) — Is a vaccine which will prevent malaria
for the rest of your child’s life.
c) — Carries no known side effect.
d) — Will correct nutritional deficiencies and
other health problems your child might
now have.
9) Malaria is caused by—
a) — Vegetation.
b) — Poor nutrition.
c) — Lack of sleep, excessive crying, and exces-
sive sadness.
d) — A bird flying over you during the night.
e) — The bite from an infected mosquito.
3) Once the study has begun—
a) — You may remove your child from the
study at any time.
b) — You may remove your child from the
study only if the study organizers say it is
OK.
c) — You may remove your child from the
study with the permission of village
leaders.
d) — You may remove your child from the
study with permission from your
husband.
4) If you decide for your child to drop out of the
study—
a) — Your child will still be given weekly
checkups, but no food or money.
b) — You will be given nothing – including no
access to healthcare services for your
children.
c) — You will be fined and punished.
d) — You will be given nothing, but will
always have access to healthcare in case
of a medical problem or emergency.
5) The purpose of this project is—
a) — To determine the cause of malaria.
b) — To provide your village with malaria
medications and health care.
c) — To study the amount of malaria and
anemia in your village and possibly
develop a cure for malaria.
d) — To provide your village with a cure for
malaria.
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